

CorMedix Inc.  
Form 8-K  
October 01, 2015

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 25, 2015

CORMEDIX INC.  
(Exact Name of Registrant as Specified in  
Charter)

Delaware (State or Other Jurisdiction of Incorporation)	001-34673 (Commission File Number)	20-5894890 (IRS Employer Identification No.)
--	--	--

1430 US  
Highway 206,  
Suite 200,  
Bedminster, NJ 07921  
(Address of  
Principal  
Executive  
Offices) (Zip  
Code)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed  
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

Item Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers  
5.02

On September 25, 2015, Harry O'Grady notified us that he is resigning as our Chief Financial Officer effective October 7, 2015. His resignation was not related to any disagreement with our company on any matter relating to our operations, policies or practices, but rather was due to accepting a job at another company. We are in the process of identifying and interviewing potential individuals to serve as our interim Chief Financial Officer while we are conducting a formal search for a Chief Financial Officer.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: October 1, 2015

By: /s/ Randy Milby  
Name: Randy Milby  
Title: Chief Executive Officer